Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

J.P. Morgan Keeps Inspire Pharmaceuticals Rating

J.P. Morgan keeps neutral on Inspire Pharmaceuticals (ISPH).

Analyst Maged Shenouda says although there were trends toward efficacy for INS327217, he anticipated a high risk. He says he's not surprised that study didn't meet its primary objective, and says he would be surprised if Inspire continues to develop the drug.

Shenouda thinks Inspire should focus on more promising partnerships, such as its program with Allergan for dry-eye, which he estimates will generate about $390 million in peak sales in 2006.

blog comments powered by Disqus